Theranexus SA (3VG) AI Stock Analysis

Theranexus SA

(Frankfurt:3VG)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Moderated DebtDebt has moderated from prior peaks and remained around €2.9m recently, which somewhat reduces leverage pressure compared with earlier periods. This improvement does not remove balance-sheet risk, but it may provide modestly greater financial flexibility while the company advances its clinical pipeline.

Negative Factors

Zero RevenueThe complete revenue drop to zero in 2025 highlights substantial commercialization and execution risk for a clinical-stage company. Without recurring product revenue, Theranexus has limited internal funding capacity and remains dependent on successfully advancing programs or securing external capital.

Theranexus SA (3VG) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 47.79M
Dividend Yield: ―
Average Volume (3M): 1,396
Price to Earnings (P/E): -34.2
Beta (1Y): 0.45
Revenue Growth: ―
EPS Growth: 54.40%
Country: Germany
Employees: 12
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Theranexus SA Business Overview & Revenue Model

Company Description

Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation f...

Theranexus SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:3VG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:MEDCL	50Neutral	EUR 948.13M	-28.97	―	―	-23.21%	-50.69%
FR:ALSEN	45Neutral	EUR 87.32M	-2.04	-54.15%	―	―	6.26%
FR:SIGHT	43Neutral	EUR 18.98M	-1.06	52.39%	―	-610.31%	43.88%
FR:AB	39Underperform	EUR 52.22M	-6.72	27.28%	―	12.66%	44.01%
FR:ALINS	21Underperform	EUR 10.82M	-0.76	148.60%	―	-24.18%	-120.44%

* Healthcare Sector Average

Performance Comparison

DE:3VG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:3VG	Theranexus SA	3.38	1.59	89.36%
FR:SIGHT	GenSight Biologics	0.08	-0.06	-42.11%
FR:AB	Ab Science	0.54	-0.64	-54.07%
FR:ALSEN	Sensorion SAS	8.64	-8.46	-49.47%
FR:ALINS	Intrasense SA	0.20	-0.06	-21.15%
FR:MEDCL	MedinCell SA	26.36	-11.26	-29.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Theranexus SA AI Stock Analysis